
iSTAR Medical
Glaucoma is the second leading cause of adult blindness globally, affecting more than 90 million people. Micro-invasive glaucoma surgery (MIGS) is the most promising and fastest-growing therapeutic option in the treatment of glaucoma.
iSTAR’s lead product, MINIject ™, has been designed to be a best-in-class MIGS device. Data from its first-in-human STAR-I trial confirms that it is safe and highly effective in achieving significant IOP reduction, as well as easing medication burden in glaucoma patients. Several additional studies are in progress to support iSTAR’s market entry plans into Europe and the United States.
iSTAR has raised €55 million to-date.
1) Recent Milestones: Over 2,500 patients worldwide have now been implanted with MINIject®, iSTAR Medical’s minimally invasive glaucoma surgical (MIGS) device for patients with glaucoma In 2023, iSTAR Medical initiated its STAR-VI trial, which seeks to evaluate the safety and efficacy of MINIject® in conjunction with cataract surgery for patients with primary open-angle glaucoma Data within the STAR-LIFE study, our observational, multicentric registry focused on data collection after MINIject® implantation in a real-life setting, continues to show and establish a consistent safety and efficacy profile for the use of MINIject® in patients with open-angle glaucoma. iSTAR Medical’s STAR-GLOBAL study continues to progress successfully, and this year, we presented with 3-year MINIject® results data at the World Glaucoma Congress, confirming a favorable safety profile and no endothelial cell density (ECD) safety concerns. Data also showed sustained meaningful reduction in intraocular pressure (IOP) of 39%, with 42% of patients medication-free after treatment In July 2022, iSTAR Medical entered a strategic alliance with Abbvie for the further development and commercialisation of iSTAR Medical’s MINIject® device
2) Upcoming Milestones: We look forward to the further commercialisation of MINIject® in Europe, and MINIject® will soon be commercially available in the first country outside Europe in the coming weeks.
3) Products: iSTAR Medical’s lead product is MINIject®. Glaucoma is the world’s leading cause of irreversible blindness, affecting over 100 million people globally. iSTAR Medical is seeking to transform the glaucoma treatment landscape through its lead product MINIject®, a bio-integrating minimally-invasive glaucoma surgery (MIGS) device which utilises iSTAR Medical’s distinctive, tissue-integrating STAR material. MINIject® enhances natural flow in the supraciliary space, and has been shown to deliver safe, meaningful and sustained control of intraocular pressure (IOP), potentially allowing patients to discontinue topical medication usage (drops). Not only does this increase the quality of life for patients but this mitigates risks of poor patient compliance, a common issue with topical glaucoma treatment, which increases the risk of blindness. MINIject® can be implanted in the supraciliary space because of the Company’s tissue friendly STAR material. The novel, flexible and porous material conforms to the eye’s anatomy and enables greater biointegration, increasing implant durability whilst decreasing fibrosis and scarring.
4) Investors: amongst others, EQT, GIMV, Earlybird, BNP Paribas, Capricorn Health-Tech Fund, Wallonie Entreprendre (previously SRIW), SFPI and Healionics
5) Full Company address & contact details: iSTAR Medical, Avenue Sabin 6, 1300 Wavre Paul van Hagen, CFO paul.vanhagen@istar-medical.com